Related Experiment Video
Updated: Mar 5, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Hypertension up to date: SPRINT to SPYRAL
Saarraaken Kulenthiran1, Sebastian Ewen2, Michael Böhm2
1Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str., IMED, 66421, Homburg (Saar), Germany. Saarraaken.Kulenthiran@uks.eu.
Abstract:
Hypertension is the most common chronic cardiovascular condition with increasing prevalence all over the world. Treatment of patients at risk requires a multimodal therapeutic concept to adjust blood pressure, including systematic identification of secondary causes of hypertension or pseudo-resistance, lifestyle modification, polypharmacy, and as well as accompanying risk factors and comorbidities. The present review discusses recent studies on patients with increased cardiovascular risk potentially influencing future treatment strategies. It covers blood pressure targets in patients at risk (SPRINT), novel treatment options such as angiotensin receptor neprilysin inhibitors, discusses the treatment of patients with impaired glucose tolerance, and appreciates novelties in controlling therapy-resistant hypertension by fourth-line pharmacotherapies (PATHWAY), as well as new interventional approaches.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension III: Clinical Manifestations and Diagnostic Studies
Atherosclerosis III: Management
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hypertension I: Introduction
Antihypertensive Drugs: Direct Renin Inhibitors
